SCIENTURE HOLDINGS, INC. Adjustments to Additional Paid in Capital, Other
SCIENTURE HOLDINGS, INC. (SCNX) reported Adjustments to Additional Paid in Capital, Other of $1.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-08-13
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-12-31 was $0.00.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was -$497.62K.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-06-30 was $1.05M.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for the quarter ending 2025-03-31 was $534.80K.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for fiscal 2025 was $1.09M.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for fiscal 2021 was $21.64K, a 61.96% decline from fiscal 2020.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for fiscal 2020 was $56.88K, a 46.06% decline from fiscal 2019.
- SCIENTURE HOLDINGS, INC. adjustments to additional paid in capital, other for fiscal 2019 was $105.45K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 6 month as first filed | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$497.62K derived: sum of 2 quarters · filed 2026-03-30 | $554.59K derived: sum of 3 quarters · filed 2026-08-13 | $1.09M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$497.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $554.59K derived: sum of 2 quarters · filed 2026-08-13 | $1.09M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.59M 10-Q · filed 2026-08-13 | $534.80K 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $534.80K 10-Q · filed 2026-05-15 | ||||
| 2021-12-31 | $21.64K 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $21.64K 10-Q · filed 2022-11-07 | ||||
| 2020-12-31 | $56.88K 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $48.77K 10-Q · filed 2021-10-25 | $70.07K derived: sum of 2 quarters · filed 2021-10-25 | $149.16K derived: sum of 3 quarters · filed 2021-10-25 | ||
| 2020-06-30 | $21.29K 10-Q · filed 2021-10-25 | $100.38K derived: sum of 2 quarters · filed 2021-10-25 | |||
| 2020-03-31 | $79.09K 10-Q · filed 2021-10-25 | ||||
| 2019-12-31 | $105.45K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |